Advertisement
Screener

PACIRA BIOSCIENCES, INC. (PCRX) Interest Expense

2.8 / 5 stars · 68/120 Roast Me

PACIRA BIOSCIENCES, INC. Interest Expense

PACIRA BIOSCIENCES, INC. (PCRX) reported Interest Expense of $3.32 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.

Discontinued › Expense Statement

us-gaap:InterestExpense · last filed 2024-05-07

  • PACIRA BIOSCIENCES, INC. interest expense for the quarter ending 2024-03-31 was $3.32M, a 65.42% decline year-over-year.
  • PACIRA BIOSCIENCES, INC. interest expense for the quarter ending 2023-12-31 was $3.39M, a 69.31% decline year-over-year.
  • PACIRA BIOSCIENCES, INC. interest expense for the quarter ending 2023-09-30 was $3.46M, a 64.85% decline year-over-year.
  • PACIRA BIOSCIENCES, INC. interest expense for the quarter ending 2023-06-30 was $3.87M, a 56.24% decline year-over-year.
  • PACIRA BIOSCIENCES, INC. interest expense for fiscal 2023 was $20.31M, a 49.20% decline from fiscal 2022.
  • PACIRA BIOSCIENCES, INC. interest expense for fiscal 2022 was $39.98M, a 25.91% increase from fiscal 2021.
  • PACIRA BIOSCIENCES, INC. interest expense for fiscal 2021 was $31.75M, a 23.68% increase from fiscal 2020.
  • PACIRA BIOSCIENCES, INC. interest expense for fiscal 2020 was $25.67M, a 8.65% increase from fiscal 2019.
Period endInterest Expense 3 monthInterest Expense 6 monthInterest Expense 9 monthInterest Expense 12 month
2024-03-31$3.32M
10-Q · filed 2024-05-07
$6.70M
derived: sum of 2 quarters · filed 2024-05-07
$10.17M
derived: sum of 3 quarters · filed 2024-05-07
$14.03M
derived: sum of 4 quarters · filed 2024-05-07
2023-12-31$3.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$6.85M
derived: sum of 2 quarters · filed 2024-02-29
$10.72M
derived: sum of 3 quarters · filed 2024-02-29
$20.31M
10-K · filed 2024-02-29
2023-09-30$3.46M
10-Q · filed 2023-11-02
$7.33M
derived: sum of 2 quarters · filed 2023-11-02
$16.92M
10-Q · filed 2023-11-02
$27.96M
derived: sum of 4 quarters · filed 2024-05-07
2023-06-30$3.87M
10-Q · filed 2023-08-02
$13.45M
10-Q · filed 2023-08-02
$24.50M
derived: sum of 3 quarters · filed 2024-05-07
$34.35M
derived: sum of 4 quarters · filed 2024-05-07
2023-03-31$9.59M
10-Q · filed 2024-05-07
$20.63M
derived: sum of 2 quarters · filed 2024-05-07
$30.49M
derived: sum of 3 quarters · filed 2024-05-07
$39.32M
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31$11.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$20.90M
derived: sum of 2 quarters · filed 2024-02-29
$29.73M
derived: sum of 3 quarters · filed 2024-02-29
$39.98M
10-K · filed 2024-02-29
2022-09-30$9.86M
10-Q · filed 2023-11-02
$18.69M
derived: sum of 2 quarters · filed 2023-11-02
$28.93M
10-Q · filed 2023-11-02
$39.36M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$8.83M
10-Q · filed 2023-08-02
$19.08M
10-Q · filed 2023-08-02
$29.50M
derived: sum of 3 quarters · filed 2024-02-29
$36.84M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$10.25M
10-Q · filed 2023-05-03
$20.67M
derived: sum of 2 quarters · filed 2024-02-29
$28.00M
derived: sum of 3 quarters · filed 2024-02-29
$35.02M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$10.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$17.76M
derived: sum of 2 quarters · filed 2024-02-29
$24.78M
derived: sum of 3 quarters · filed 2024-02-29
$31.75M
10-K · filed 2024-02-29
2021-09-30$7.33M
10-Q · filed 2022-11-03
$14.36M
derived: sum of 2 quarters · filed 2022-11-03
$21.33M
10-Q · filed 2022-11-03
$28.39M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$7.02M
10-Q · filed 2022-08-03
$13.99M
10-Q · filed 2022-08-03
$21.06M
derived: sum of 3 quarters · filed 2023-02-28
$28.19M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$6.97M
10-Q · filed 2022-05-04
$14.03M
derived: sum of 2 quarters · filed 2023-02-28
$21.16M
derived: sum of 3 quarters · filed 2023-02-28
$26.62M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$7.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$14.19M
derived: sum of 2 quarters · filed 2023-02-28
$19.65M
derived: sum of 3 quarters · filed 2023-02-28
$25.67M
10-K · filed 2023-02-28
2020-09-30$7.13M
10-Q · filed 2021-11-03
$12.59M
derived: sum of 2 quarters · filed 2021-11-03
$18.61M
10-Q · filed 2021-11-03
$24.61M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$5.46M
10-Q · filed 2021-08-03
$11.48M
10-Q · filed 2021-08-03
$17.48M
derived: sum of 3 quarters · filed 2022-02-28
$23.41M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$6.02M
10-Q · filed 2021-05-04
$12.02M
derived: sum of 2 quarters · filed 2022-02-28
$17.96M
derived: sum of 3 quarters · filed 2022-02-28
$23.84M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$6.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$11.94M
derived: sum of 2 quarters · filed 2022-02-28
$17.82M
derived: sum of 3 quarters · filed 2022-02-28
$23.63M
10-K · filed 2022-02-28
2019-09-30$5.94M
10-Q · filed 2020-10-30
$11.82M
derived: sum of 2 quarters · filed 2020-10-30
$17.63M
10-Q · filed 2020-10-30
$23.39M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$5.88M
10-Q · filed 2020-08-06
$11.69M
10-Q · filed 2020-08-06
$17.45M
derived: sum of 3 quarters · filed 2021-03-01
$23.09M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$5.81M
10-Q · filed 2020-05-07
$11.57M
derived: sum of 2 quarters · filed 2021-03-01
$17.21M
derived: sum of 3 quarters · filed 2021-03-01
$22.61M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$5.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$11.40M
derived: sum of 2 quarters · filed 2021-03-01
$16.79M
derived: sum of 3 quarters · filed 2021-03-01
$21.95M
10-K · filed 2021-03-01
2018-09-30$5.64M
10-Q · filed 2019-11-08
$11.04M
derived: sum of 2 quarters · filed 2019-11-08
$16.20M
10-Q · filed 2019-11-08
$21.30M
derived: sum of 4 quarters · filed 2020-02-21
2018-06-30$5.40M
10-Q · filed 2019-08-08
$10.55M
10-Q · filed 2019-08-08
$15.66M
derived: sum of 3 quarters · filed 2020-02-21
$20.79M
derived: sum of 4 quarters · filed 2020-02-21
2018-03-31$5.16M
10-Q · filed 2019-05-02
$10.26M
derived: sum of 2 quarters · filed 2020-02-21
$15.39M
derived: sum of 3 quarters · filed 2020-02-21
$20.61M
derived: sum of 4 quarters · filed 2020-02-21
2017-12-31$5.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21
$10.23M
derived: sum of 2 quarters · filed 2020-02-21
$15.46M
derived: sum of 3 quarters · filed 2020-02-21
$18.05M
10-K · filed 2020-02-21
2017-09-30$5.13M
10-Q · filed 2018-11-01
$10.35M
derived: sum of 2 quarters · filed 2018-11-01
$12.94M
10-Q · filed 2018-11-01
$14.80M
derived: sum of 4 quarters · filed 2019-02-28
2017-06-30$5.23M
10-Q · filed 2018-08-02
$7.82M
10-Q · filed 2018-08-02
$9.67M
derived: sum of 3 quarters · filed 2019-02-28
$11.27M
derived: sum of 4 quarters · filed 2019-02-28
2017-03-31$2.59M
10-Q · filed 2018-05-03
$4.45M
derived: sum of 2 quarters · filed 2019-02-28
$6.05M
derived: sum of 3 quarters · filed 2019-02-28
$7.78M
derived: sum of 4 quarters · filed 2019-02-28
2016-12-31$1.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28
$3.46M
derived: sum of 2 quarters · filed 2019-02-28
$5.19M
derived: sum of 3 quarters · filed 2019-02-28
$7.06M
10-K · filed 2019-02-28
2016-09-30$1.60M
10-Q · filed 2017-11-08
$3.33M
derived: sum of 2 quarters · filed 2017-11-08
$5.20M
10-Q · filed 2017-11-08
$7.08M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30$1.73M
10-Q · filed 2017-08-02
$3.60M
10-Q · filed 2017-08-02
$5.48M
derived: sum of 3 quarters · filed 2018-02-28
$7.39M
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$1.87M
10-Q · filed 2017-05-04
$3.75M
derived: sum of 2 quarters · filed 2018-02-28
$5.66M
derived: sum of 3 quarters · filed 2018-02-28
$7.60M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31$1.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28
$3.79M
derived: sum of 2 quarters · filed 2018-02-28
$5.73M
derived: sum of 3 quarters · filed 2018-02-28
$7.72M
10-K · filed 2018-02-28
2015-09-30$1.91M
10-Q · filed 2016-11-02
$3.85M
derived: sum of 2 quarters · filed 2016-11-02
$5.84M
10-Q · filed 2016-11-02
$14.12M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$1.94M
10-Q · filed 2016-08-04
$3.94M
10-Q · filed 2016-08-04
$12.21M
derived: sum of 3 quarters · filed 2017-03-01
$14.25M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$2.00M
10-Q · filed 2016-05-02
$10.27M
derived: sum of 2 quarters · filed 2017-03-01
$12.31M
derived: sum of 3 quarters · filed 2017-03-01
$14.39M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$8.28M
10-K · filed 2017-03-01
$10.31M
derived: sum of 2 quarters · filed 2017-03-01
$12.39M
derived: sum of 3 quarters · filed 2017-03-01
$8.28M
10-K · filed 2016-02-25
2014-09-30$2.04M
10-Q · filed 2015-10-27
$4.12M
derived: sum of 2 quarters · filed 2015-10-27
$6.22M
10-Q · filed 2015-10-27
$8.15M
derived: sum of 4 quarters · filed 2016-02-25
2014-06-30$2.08M
10-Q · filed 2015-07-30
$4.18M
10-Q · filed 2015-07-30
$6.11M
derived: sum of 3 quarters · filed 2016-02-25
$8.01M
derived: sum of 4 quarters · filed 2016-02-25
2014-03-31$2.11M
10-Q · filed 2015-04-30
$4.04M
derived: sum of 2 quarters · filed 2016-02-25
$5.93M
derived: sum of 3 quarters · filed 2016-02-25
$7.84M
derived: sum of 4 quarters · filed 2016-02-25
2013-12-31$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$3.82M
derived: sum of 2 quarters · filed 2016-02-25
$5.73M
derived: sum of 3 quarters · filed 2016-02-25
$7.25M
10-K · filed 2016-02-25
2013-09-30$1.89M
10-Q · filed 2014-10-30
$3.81M
derived: sum of 2 quarters · filed 2014-10-30
$5.33M
10-Q · filed 2014-10-30
$5.67M
derived: sum of 4 quarters · filed 2015-02-24
2013-06-30$1.91M
10-Q · filed 2014-07-31
$3.43M
10-Q · filed 2014-07-31
$3.78M
derived: sum of 3 quarters · filed 2015-02-24
$4.23M
derived: sum of 4 quarters · filed 2015-02-24
2013-03-31$1.52M
10-Q · filed 2014-05-01
$1.86M
derived: sum of 2 quarters · filed 2015-02-24
$2.32M
derived: sum of 3 quarters · filed 2015-02-24
$2.81M
derived: sum of 4 quarters · filed 2015-02-24
2012-12-31$343.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24
$799.00K
derived: sum of 2 quarters · filed 2015-02-24
$1.29M
derived: sum of 3 quarters · filed 2015-02-24
$1.81M
10-K · filed 2015-02-24
2012-09-30$456.00K
10-Q · filed 2013-10-31
$950.00K
derived: sum of 2 quarters · filed 2013-10-31
$1.46M
10-Q · filed 2013-10-31
$2.18M
derived: sum of 4 quarters · filed 2014-02-25
2012-06-30$494.00K
10-Q · filed 2013-08-06
$1.01M
10-Q · filed 2013-08-06
$1.72M
derived: sum of 3 quarters · filed 2014-02-25
$2.63M
derived: sum of 4 quarters · filed 2014-02-25
2012-03-31$514.00K
10-Q · filed 2013-05-08
$1.23M
derived: sum of 2 quarters · filed 2014-02-25
$2.14M
derived: sum of 3 quarters · filed 2014-02-25
$2.81M
derived: sum of 4 quarters · filed 2014-02-25
2011-12-31$712.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
$1.62M
derived: sum of 2 quarters · filed 2014-02-25
$2.30M
derived: sum of 3 quarters · filed 2014-02-25
$4.78M
10-K · filed 2014-02-25
2011-09-30$910.00K
10-Q · filed 2012-11-01
$1.59M
derived: sum of 2 quarters · filed 2012-11-01
$4.07M
10-Q · filed 2012-11-01
$5.45M
derived: sum of 4 quarters · filed 2013-03-07
2011-06-30$676.00K
10-Q · filed 2012-08-09
$3.16M
10-Q · filed 2012-08-09
$4.54M
derived: sum of 3 quarters · filed 2013-03-07
$5.62M
derived: sum of 4 quarters · filed 2013-03-07
2011-03-31$2.48M
10-Q · filed 2012-05-09
$3.86M
derived: sum of 2 quarters · filed 2013-03-07
$4.94M
derived: sum of 3 quarters · filed 2013-03-07
$5.83M
derived: sum of 4 quarters · filed 2013-03-07
2010-12-31$1.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07
$2.46M
derived: sum of 2 quarters · filed 2013-03-07
$3.35M
derived: sum of 3 quarters · filed 2013-03-07
$3.96M
10-K · filed 2013-03-07
2010-09-30$1.08M
10-Q · filed 2011-10-31
$1.96M
derived: sum of 2 quarters · filed 2011-10-31
$2.58M
10-Q · filed 2011-10-31
2010-06-30$887.00K
10-Q · filed 2011-08-11
$1.50M
10-Q · filed 2011-08-11
2009-12-31$1.72M
10-K · filed 2012-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Savara Inc (SVRA)United States$1.044B-9.10
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93